| Overall survival after treatment for metastatic uveal melanoma: a systematic review and meta-analysis |
21 |
| Tolerance and outcomes of stereotactic radiosurgery combined with anti-programmed cell death-1 (pembrolizumab) for melanoma brain metastases |
19 |
| RNA m(6)A methyltransferase METTL3 regulates invasiveness of melanoma cells by matrix metallopeptidase 2 |
17 |
| Amelanotic melanoma |
15 |
| Stereotactic radiosurgery combined with immune checkpoint inhibitors or kinase inhibitors for patients with multiple brain metastases of malignant melanoma |
14 |
| F-18-FDG PET/CT longitudinal studies in patients with advanced metastatic melanoma for response evaluation of combination treatment with vemurafenib and ipilimumab |
14 |
| Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series |
14 |
| Sarcoid-like reactions in patients receiving modern melanoma treatment |
14 |
| Long noncoding RNA ZFAS1 promotes tumorigenesis through regulation of miR-150-5p/RAB9A in melanoma |
12 |
| Immune checkpoint inhibitor therapy in a liver transplant recipient with a rare subtype of melanoma: a case report and literature review |
11 |
| Serum exosomal microRNAs as potent circulating biomarkers for melanoma |
11 |
| Expression and clinical significance of S100 family genes in patients with melanoma |
11 |
| The number and localization of CD68+and CD163+macrophages in different stages of cutaneous melanoma |
11 |
| Prognostic and predictive role of elevated lactate dehydrogenase in patients with melanoma treated with immunotherapy and BRAF inhibitors: a systematic review and meta-analysis |
10 |
| Clinical experience with combination BRAF/MEK inhibitors for melanoma with brain metastases: a real-life multicenter study |
9 |
| Rapid BRAF mutation tests in patients with advanced melanoma: comparison of immunohistochemistry, Droplet Digital PCR, and the Idylla Mutation Platform |
9 |
| Results from phase II trial of HSP90 inhibitor, STA-9090 (ganetespib), in metastatic uveal melanoma |
9 |
| Lymphocytic gastritis induced by pembrolizumab in a patient with metastatic melanoma |
9 |
| Immune checkpoint inhibitor (anti-CTLA- anti-PD-1) therapy alone versus immune checkpoint inhibitor (anti-CTLA- anti-PD-1) therapy in combination with anti-RANKL denosumuab in malignant melanoma: a retrospective analysis at a tertiary care center |
8 |
| Long noncoding RNA X-inactive specific transcript promotes malignant melanoma progression and oxaliplatin resistance |
8 |
| Acute progressive neuropathy-myositis-myasthenia-like syndrome associated with immune-checkpoint inhibitor therapy in patients with metastatic melanoma |
8 |
| Phase IIIb safety results from an expanded-access protocol of talimogene laherparepvec for patients with unresected, stage IIIB-IVM1c melanoma |
8 |
| The clinical significance of KIT mutations in melanoma: a meta-analysis |
7 |
| Innate immune cell infiltration in melanoma metastases affects survival and is associated with BRAF(V600E) mutation status |
7 |
| Pregnancy with successful foetal and maternal outcome in a melanoma patient treated with nivolumab in the first trimester: case report and review of the literature |
7 |
| Melanoma signature in Brazil: epidemiology, incidence, mortality, and trend lessons from a continental mixed population country in the past 15 years |
7 |
| Potential clinical and immunotherapeutic utility of talimogene laherparepvec for patients with melanoma after disease progression on immune checkpoint inhibitors and BRAF inhibitors |
6 |
| Biomarkers, measured during therapy, for response of melanoma patients to immune checkpoint inhibitors: a systematic review |
6 |
| The impact of patient characteristics and disease-specific factors on first-line treatment decisions for BRAF-mutated melanoma: results from a European expert panel study |
6 |
| Subacute cutaneous lupus erythematosus induced by nivolumab: two case reports and a literature review |
6 |
| Physiologic colonic fluorine-18-fluorodeoxyglucose uptake may predict response to immunotherapy in patients with metastatic melanoma |
6 |
| Isolation and characterization of circulating melanoma cells by size filtration and fluorescent in-situ hybridization |
6 |
| Acral melanoma: a retrospective cohort from the Brazilian National Cancer Institute (INCA) |
6 |
| Real-world performance and utility of a noninvasive gene expression assay to evaluate melanoma risk in pigmented lesions |
6 |
| Prognostic factors for first-line therapy and overall survival of metastatic uveal melanoma: The Princess Margaret Cancer Centre experience |
6 |
| Three antigen-loading methods in dendritic cell vaccines for metastatic melanoma |
6 |
| Survival trends among patients with metastatic melanoma in the pretargeted and the post-targeted era: a US population-based study |
5 |
| Global microRNA profiling of metastatic conjunctival melanoma |
5 |
| Prognostic significance of CD163 expression and its correlation with cyclooxygenase-2 and vascular endothelial growth factor expression in cutaneous melanoma |
5 |
| Incidence and prognosis of brain metastases in cutaneous melanoma patients: a population-based study |
5 |
| Nicotinamide N-methyltransferase: potential involvement in cutaneous malignant melanoma |
5 |
| Clinical and radiological response of BRAF inhibition and MEK inhibition in patients with brain metastases from BRAF-mutated melanoma |
5 |
| Metastatic acral lentiginous melanoma in a tertiary referral center in Switzerland: a systematic analysis |
5 |
| Postsurgical treatment landscape and economic burden of locoregional and distant recurrence in patients with operable nonmetastatic melanoma |
5 |
| Lymphoid aggregates in desmoplastic melanoma have features of tertiary lymphoid structures |
5 |
| Incomplete Vogt-Koyanagi-Harada disease following treatment with encorafenib and binimetinib for metastatic melanoma |
4 |
| MiR-135b is a novel oncogenic factor in cutaneous melanoma by targeting LATS2 |
4 |
| Immune-related pancreatitis associated with checkpoint blockade in melanoma |
4 |
| Mycophenolate mofetil alongside high-dose corticosteroids: optimizing the management of combination immune checkpoint inhibitor-induced colitis |
4 |
| Expression of cancer/testis antigens in cutaneous melanoma: a systematic review |
4 |
